Consolidated 2017 revenue: €9.1 million Discontinuation of the Prestizia activity and termination of agreements with HOB Biotech, entailing exceptional charges of €3.7 million Net loss of €2.2 million excluding exceptional charges and €0.8 million for 2017 at…
Lisa Tracker® monitoring tests to be offered with Biogaran’s biosimilar drugs Croissy-Beaubourg, March 28, 2018, 6:00pm CEST – THERADIAG (ISIN code: FR0004197747, Ticker: ALTER), a company specialized in in vitro diagnostics and theranostics, is today announcing that it…
Croissy-Beaubourg, March 26, 2018, 5:45pm CEST – THERADIAG (ISIN: FR0004197747, Ticker: ALTER), a company specializing in theranostics and in vitro diagnostics, announces today its financial reporting schedule for 2018. Financial publications will be released after market…